Global Chronic Obstructive Pulmonary Disease Treatment Market to Hit $11.2 Billion by 2021
The global treatment market for Chronic Obstructive Pulmonary Disease (COPD) will rise steadily from $9.2 billion in 2014 to $11.2 billion in 2021, at a compound annual growth rate of 2.9%. The COPD therapeutics market landscape over the forecast period will be characterized by the sales erosion of leading brands. Currently, the market is dominated by three brands, namely Pfizer’s Spiriva, GlaxoSmithKline’s (GSK’s) Advair and AstraZeneca’s Symbicort, which have all generated multi-billion dollar revenues to date. The patents for these leading brands have either expired or will do very soon, leaving the market open to generic competition, which will impact negatively on these brands’ sales figures. The market, which used to be dominated by only a few brands, will become more fragmented and will see the introduction of various brands with similar characteristics.
GBI Research’s COPD Therapeutics in Major Developed Markets in 2021 – Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands report provides analysis of the Chronic Obstructive Pulmonary Disease (COPD) treatment pipeline, by stage of development, molecule type, and molecular target. It provides information on the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in COPD.
Single User Price: $4,995